Skip to main content

Branded

  • Actavis appoints board of directors for Irish division following Irish High Court clearance of Warner Chilcott deal

    DUBLIN — Actavis has appointed the board of directors for the division it recently created as part of its acquisition of Ireland-based Warner Chilcott, the drug maker said.

    Actavis, which announced the $8.5 billion purchase of Warner Chilcott, cleared the final regulatory hurdle to the acquisition Monday when the Irish High Court approved it. As part of the acquisition, it is changing Warner Chilcott's name to Actavis plc.

  • HDMA re-elects chair and vice chair, names two new board members

    ARLINGTON, Va. — The Healthcare Distribution Management Association on Tuesday announced the re-election of David Neu, president of AmerisourceBergen Drug Corp. as chairman of its board of directors. Ted Scherr, president and CEO of Dakota Drug, also was re-elected as vice chairman.  

    Additionally, HDMA welcomed two members to the Board. Mark Walchirk, president of McKesson U.S. Pharmaceutical, was elected to replace Paul Julian, EVP and group president of McKesson Corporation, on the board and executive committee. 

  • FDA approves Takeda's Brintellix for depression

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug developed by Takeda to treat major depressive disorder, the agency said.

    The FDA announced the approval of Brintellix (vortioxetine) tablets for treating MDD in adults. The drug will be available in the 5-mg, 10-mg, 15-mg and 20-mg strengths.

  • Actavis, Warner Chilcott meet last regulatory requirements for merger

    DUBLIN — Ireland's High Court has approved Actavis' acquisition of Warner Chilcott, the drug makers said.

    The companies said the approval of Irish authorities meant that they had obtained all regulatory approvals required to complete the transaction, and that it now remained subject to satisfaction of other customary closing conditions and would occur as soon as practicable.

    Actavis and Warner Chilcott announced the $8.5 billion merger deal in May. The companies' shareholders voted to approve it on Sept. 10.

     

  • Medicare, Medicaid, Health Insurance Marketplace to continue operating amid government shutdown

    NEW YORK — The Department of Health and Human Services will furlough more than half of its employees due to the government shutdown, the agency said.

    In announcing a contingency staffing plan for the shutdown, which started Tuesday when Congress failed to pass a budget in time, HHS said 52% of its employees would be on furlough, totaling 40,512 members of its staff. The remaining 48%, or 37,686 employees, would remain. The scheduled introduction of the health insurance exchanges mandated under the Patient Protection and Affordable Care Act will also continue.

  • FDA approves Genentech's Perjeta for early-stage breast cancer

    SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for treating early-stage breast cancer before surgery, the agency said Monday.

  • FDA approves UCB's Cimzia for psoriatic arthritis

    BRUSSELS — The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.

    UCB announced the approval of Cimzia (certolizumab pegol) for psoriatic arthritis in adults. Psoriatic arthritis is an inflammatory, autoimmune condition that causes pain, swelling and stiffness around the joints, usually combined with the skin lesions of psoriasis. The drug was already approved to treat rheumatoid arthritis and Crohn's disease.

  • HDMA supports national pharmaceutical traceability legislation

    ARLINGTON, Va. — The Healthcare Distribution Management Association on Saturday added its voice supporting national pharmaceutical traceability legislation (Drug Quality and Security Act/H.R. 3204). 

X
This ad will auto-close in 10 seconds